We are live on ! Find out more
IMDZ

Immune Design Corp.
IMDZ

Delisted

IMDZ was delisted on the 1st of April, 2019.

64 hedge funds and large institutions have $39M invested in Immune Design Corp. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

10% less funds holding

Funds holding: 7164 (-7)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

49% less capital invested

Capital invested by funds: $76.9M → $39M (-$37.8M)

Holders
64
Holders Change
-7
Holders Change %
-9.86%
% of All Funds
1.43%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
10
Increased
28
Reduced
15
Closed
16
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
76
Alambic Investment Management
California
-$45K -13,000 Closed
Marshall Wace
77
Marshall Wace
United Kingdom
-$36K -10,298 Closed
IP
78
Intellectus Partners
California
-$1.74K -1,000 Closed
CG
79
Cutler Group
California
+$174 +100 New

IMDZ Hedge Fund Activity: Q4 2018 in Review

64 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q4 2018, worth a combined $39M — down 49% from $76.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of IMDZ and 10 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 28 added.

The largest buyer was EcoR1 Capital, adding an estimated $5.84M. The largest seller was Portolan Capital Management, exiting entirely with an estimated $2.5M sold.

  • 64 institutional investors held Immune Design Corp. (IMDZ) as of Q4 2018, down from 71 in Q3 2018.
  • Funds reported $39M of Immune Design Corp. stock for Q4 2018, down 49% quarter-over-quarter.
  • 10 funds opened new Immune Design Corp. positions in Q4 2018 and 16 closed out, a net change of -6 holders.
  • The largest Immune Design Corp. buyer in Q4 2018 was EcoR1 Capital, an estimated $5.84M added.
  • The largest Immune Design Corp. seller in Q4 2018 was Portolan Capital Management, an estimated $2.5M sold.

Based on aggregated 13F filings for Q4 2018.